Cost-effectiveness of HIV/AIDS interventions in Africa: A systematic review of the evidence

Lancet

Volumn 359, Issue 9318, 2002, Pages 1635-1642

  Creese, Andrew ^a   Floyd, Katherine ^a   Alban, Anita ^b   Guinness, Lorna ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; BLOOD BANK; CALCULATION; CONDOM; COST EFFECTIVENESS ANALYSIS; COUNSELING; DATA BASE; DISABILITY; DRUG COST; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT FEEDING; INFECTION PREVENTION; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; TUBERCULOSIS;

EID: 0037062185     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08595-1     Document Type: Article

References (48)

1. Fighting global AIDS: The value of cost-effectiveness analysis
2. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialised countries
3. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV
4. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries
5. Cost-effectiveness of short course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting
6. Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa
7. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: An issue of cost-effectiveness and capacity
8. Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa
9. Cost effectiveness of tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa
10. Cost and impact of home-based care for people living with HIV/AIDS in Zambia
11. Costs and cost-effectiveness of community-based DOTS vs conventional treatment in Africa
12. Benefits of HIV screening of blood transfusions in Zambia
13. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania
14. Cost effectiveness of single dose nevirapine regimen for mothers and babies to decrease vertical transmission in sub-Saharan Africa
15. Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe
16. Controlling HIV in Africa: Effectiveness and cost of an intervention in a high-frequency STD transmitter core group
17. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries
18. Prevention of vertical transmission of HIV: Analysis of cost effectiveness of options available in South Africa
19. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania
20. National and provincial estimated costs and cost-effectiveness of a programme to reduce mother-to-child transmission in South Africa
21. An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda
22. The cost of home-based care for HIV/AIDS patients in Zimbabwe
23. Cost-effectiveness of chemotherapy for sputum smear-positive pulmonary tuberculosis in Malawi, Mozambique and Tanzania
24. Cost-effective use of nevirapine to prevent vertical HIV transmission in Sub-Saharan Africa
25. Feasibility of hospital-based blood banking: A Tanzanian case study
26. The real and the nominal? Making inflationary adjustments to cost and other economic data
27. The role of cost-effectiveness analysis in health and medicine
28. The AIDS Epidemic and its Demographic Consequences
29. Prospects for worldwide tuberculosis control under the WHO DOTS strategy
30. Measurement and determinants of tuberculosis outcome in Karonga District, Malawi
31. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia
32. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi
33. Economic costs of HIV/AIDS prevention activities in sub-Saharan Africa
34. Public spending on health care: How are different criteria related?